Last reviewed · How we verify
triptorelin, goserelin, leuprorelin
Triptorelin, goserelin, and leuprorelin are synthetic analogs of gonadotropin-releasing hormone (GnRH) that act as potent agonists, initially stimulating and then downregulating GnRH receptors, leading to a decrease in gonadotropin secretion and subsequently a decrease in sex hormone production.
Triptorelin, goserelin, and leuprorelin are synthetic analogs of gonadotropin-releasing hormone (GnRH) that act as potent agonists, initially stimulating and then downregulating GnRH receptors, leading to a decrease in gonadotropin secretion and subsequently a decrease in sex hormone production. Used for Prostate cancer, Breast cancer, Endometriosis.
At a glance
| Generic name | triptorelin, goserelin, leuprorelin |
|---|---|
| Sponsor | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This mechanism is primarily used in the treatment of hormone-sensitive cancers, such as prostate cancer and breast cancer. By reducing sex hormone production, these drugs can slow or stop the growth of cancer cells. Additionally, they can be used to treat conditions such as endometriosis and precocious puberty.
Approved indications
- Prostate cancer
- Breast cancer
- Endometriosis
- Precocious puberty
Common side effects
- Hot flashes
- Nausea
- Headache
- Injection site reaction
- Fatigue
Key clinical trials
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (PHASE3)
- A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PHASE3)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: